Skip to main content
OpenTrials
Completed

NCT Number: NCT02466217

Phenomics in Autoimmune and Inflammatory Diseases

The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa. Cross phenotyping of patients with IAD should be heuristic and help revise the nosography and the understanding of these diseases.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CIC Paris-Est, Hôpital PITIE SALPETRIERE, Paris, France

Loading trial locations.

About this study

The family of inflammatory/autoimmune systemic diseases (IAD) represents a large group of human diseases. For most if not all of these IAD, the pathophysiological processes or exact causes remain poorly understood. Progresses in molecular understanding of these IAD have led to realize that these are not two distinct categories of diseases. Rather they form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa.

Using systems biology, the investigator aims to improve the understanding of these diseases, to identify novel genes/pathways involved, specific or across the diseases, and to discover biomarkers and potential therapeutic targets.

The investigator will study adult patients with at least one of the following IAD: Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndromes (CAPS) /Tumor Necrosis Factor-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes. This panel will be completed by controls groups: healthy volunteers, and patients with arthritis (knee and/or hip) or muscular dystrophy.

The biological investigations will notably comprise: immunomics (comprehensive evaluation of peripheral blood cell subsets and serum immunoproteomics, including autoantibodies); transcriptomics; Human Leukocyte Antigen (HLA)-phenotyping; genomics; T-Cell Receptor (TCR) sequencing and microbiota studies.

After signing the informed consent, the subject attends only one visit (Day 0) during which all biological samples will be taken and all clinical information collected.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presenting either:
  • one IAD from our list (Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/Tumor Necrosis Factor (TNF)-receptor Associated Periodic Syndrome, Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes)
  • or an unclassified IAD : a knee and/or hip arthritis or a muscular dystrophy
  • or healthy subject
  • Good veins
  • Affiliation to a social security system
  • Informed consent form, signed by the participant and the investigator, prior all needed examination

Exclusion criteria

  • For IADs patients
  • Unauthorized treatment (anticancer chemotherapy)
  • For Healthy volunteers
  • Contra-indications for donating blood except from age
  • Known history of IAD (eg: Psoriasis)
  • Common exclusion criteria:
  • Pregnant woman
  • Still under the exclusion period from another biomedical study
  • Psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent
  • Patient under a legal protection
  • Chronic lifelong viral infection unrelated to the pathology
  • Mild infection within the last 3 months

Treatment and study plan

1: AID groups

Other

Clinical and Biological investigations

2: Control groups

Other

Clinical and Biological investigations

Primary outcomes

  1. Total peripheral blood gene expression between patients, expressed as fluorescence intensity

    Time frame: at day 0, no follow-up

    Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach

  2. Tregs and Tconvs T cell receptor repertoire, expressed as the % of unique TCR sequences

    Time frame: at day 0, no follow-up

    Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach

  3. HLA type and SNPs expressed as the occurrence events across patients

    Time frame: at day 0, no follow-up

    Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach

  4. Microbiote species identification expressed as the % of species per family and genus

    Time frame: at day 0, no follow-up

    Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach

  5. Cytokines and chemokines expressed as fluorescence intensity

    Time frame: at day 0, no follow-up

    Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach

  6. Immune cells phenotyping expressed as the each cell type % within total PBMCs

    Time frame: at day 0, no follow-up

    Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach

Secondary outcomes

  1. Changes in gene expression intensity between patients and healthy controls - for each Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  2. Changes in Tregs and Tconvs TCR sequence frequencies between patients and healthy controls - for each Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  3. Characterization of HLA and SNP profiles in patients and healthy controls - for each Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  4. Changes in Microbiote composition between patients and healthy controls - for each Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  5. Changes in cytokines and chemokines expression levels between patients and healthy controls - for each Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  6. Changes in immune cells frequencies between patients and healthy controls - for each Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  7. Identification of specific and common gene expression levels between patients - between Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  8. Identification of specific and common Tregs and Tconvs TCR sequence frequencies between patients - between Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  9. Characterization of specific and common HLA and SNP profiles in patients - between Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  10. Identification of specific and common microbiote composition between patients - between Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  11. Identification of specific and common cytokines and chemokines expression levels between patients - between Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

  12. Characterization specific and common variations in immune cells frequencies between patients - between Disease cohorts

    Time frame: at day 0, no follow-up

    Identification of new biomarkers and potential therapeutic by multiscale analysis

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • National Research Agency, France

Registry information

Official study title

Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases

Acronym: TRANSIMMUNOM

Important dates

Study start
2015
Primary completion
2022
Study completion
2022
First posted
Jun 9, 2015
Registry last updated
Aug 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.